Semaglutide 25MG

Semaglutide 25MG

$325.00

Semaglutide is a potent synthetic peptide that mimics the GLP-1 hormone, which plays a crucial role in regulating blood sugar levels and appetite. Widely recognized for its effectiveness in managing type 2 diabetes and obesity, Semaglutide enhances insulin secretion, reduces glucagon release, and slows gastric emptying, leading to improved glycemic control and weight loss. Its dual benefits make it a valuable option in both research and therapeutic settings aimed at enhancing metabolic health and supporting weight management.

Out of stock

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and as an anti-obesity medication for long-term weight management. It is a synthetic peptide that shares 94% structural homology with human GLP-1. Semaglutide works by mimicking the effects of the incretin hormone GLP-1, which plays a crucial role in regulating blood glucose levels and appetite.

Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Molecular Formula: C187H291N45O59

Molecular Weight: 4113.64 g/mol

CAS Number: 910463-68-2

  1. Glycemic Control: Semaglutide has demonstrated superior efficacy in reducing HbA1c levels compared to placebo and other diabetes medications, with a maximum reduction of 2.24% observed in clinical trials.
  2. Weight Loss: In clinical trials, semaglutide showed significant weight loss effects, with participants losing up to 22.5% of their initial body weight. In the SURMOUNT-1 trial, 36% of participants receiving the highest dose (15 mg) achieved ≥25% weight loss.
  3. Cardiovascular Benefits: The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events in adults with preexisting cardiovascular disease, overweight or obesity, without diabetes.
  4. Cardiometabolic Risk Factors: Treatment with semaglutide resulted in improvements in various cardiometabolic measures, including blood pressure, fasting insulin levels, and lipid profiles.
  5. Safety Profile: Semaglutide was associated with fewer serious adverse events compared to placebo, although it had higher rates of gastrointestinal side effects and trial product discontinuation.

  1. Long-term Safety: Extended studies are needed to evaluate the long-term safety profile of semaglutide, particularly in diverse patient populations.
  2. Expanded Indications: Research is underway to explore semaglutide's potential in treating conditions such as non-alcoholic steatohepatitis (NASH) and obesity-related heart failure with preserved ejection fraction.
  3. Combination Therapies: Future studies may investigate the potential synergistic effects of semaglutide with other therapeutic agents for enhanced metabolic control.
  4. Mechanism of Action: Further research is required to fully elucidate the molecular mechanisms by which semaglutide exerts its diverse effects, particularly the role of GIP receptor agonism.
  5. Optimal Dosing Regimens: Research into optimal delivery methods and dosing regimens for different conditions could enhance the therapeutic potential of semaglutide.

  1. Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  2. Marso, S.P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 375(19), 1834-1844. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/27633186/
  3. Bachem. (2024). Semaglutide Peptide API Manufacturer & Supply. [Online].
    Available: https://www.bachem.com/all-generic-apis/semaglutide/
  4. Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front Endocrinol, 12, 1-19. [Online].
    Available: https://www.frontiersin.org/articles/10.3389/fendo.2021.645563/full
  5. Aroda, V.R., et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724-1732. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/31186300/